Krystal Biotech, Inc. KRYS Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $225.03M+9.9% | $204.83M+3.0% | $198.91M+35.6% | $146.73M+18.4% | $123.96M+39.0% | ||
| $5.78M+2.0% | $5.67M+3.6% | $5.47M+1.9% | $5.37M-8.5% | $5.87M-0.3% | ||
| $54.65M+0.2% | $54.51M+0.8% | $54.11M-0.3% | $54.27M+1.8% | $53.31M+8.5% | ||
| —— | —— | $32.07M+127% | $14.14M-77.5% | $62.73M-8.6% | ||
| —— | —— | —— | —— | $11.59M-6.8% | ||
| —— | —— | —— | —— | —— | ||
| $5.39M-65.0% | $15.4M-9.9% | $17.1M— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $3.18M+39.5% | $2.28M-4.0% | $2.38M+8.0% | $2.2M+12.6% | $1.95M+37.6% | ||
| —— | —— | —— | —— | —— | ||
| $807K-2.4% | $827K+1.1% | $818K+2.6% | $797K+1.0% | $789K+5.6% | ||
| $250.28M+24.6% | $200.87M+14.0% | $176.2M-9.8% | $195.4M+37.0% | $142.67M+11.8% | ||
| $12.9M+7.9% | $11.95M+12.6% | $10.61M+6.6% | $9.96M+8.4% | $9.18M+117% | ||
| $444.77M+5.3% | $422.54M-14.4% | $493.55M-2.8% | $507.71M+0.1% | $507.21M+10.8% | ||
| $390.43M+3.9% | $375.64M+7.2% | $350.37M+5.0% | $333.83M+3.1% | $323.73M+8.4% | ||
| —— | —— | —— | —— | $435K— | ||
| —— | —— | -$153.36M+16.4% | -$183.4M+4.6% | -$192.23M-17.6% | ||
| $5.04M— | $0-100% | $6.97M+114% | $3.26M+122% | -$14.51M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $3.97M-85.3% | ||
| —— | —— | —— | $922K+295% | -$474K-3.5% | ||
| $192.54M+27.1% | $151.44M+713% | $18.64M+132% | $8.04M+116% | -$50.24M-273% | ||
| $15.9M+1.4% | $15.67M+8.9% | $14.39M-17.9% | $17.52M+189% | $6.07M+7.1% | ||
| -$621K-24.7% | -$498K-1,456% | -$32K+76.8% | -$138K+89.8% | -$1.36M+20.5% | ||
| $5.78M+2.0% | $5.67M+3.6% | $5.47M+1.9% | $5.37M-8.5% | $5.87M-0.3% | ||
| —— | —— | —— | —— | -$12.5M-140% | ||
| $5.39M-65.0% | $15.4M-9.9% | $17.1M— | —— | —— | ||
| $23.35M+9.8% | $21.27M-18.9% | $26.22M-12.3% | $29.91M-17.2% | $36.12M+17.2% | ||
| -$669K-15.7% | -$578K+8.1% | -$629K+8.2% | -$685K+11.0% | -$770K+7.6% | ||
| $3.18M+39.5% | $2.28M-4.0% | $2.38M+8.0% | $2.2M+12.6% | $1.95M+37.6% | ||
| —— | —— | —— | —— | $11.04M+41.2% | ||
| —— | —— | —— | —— | —— | ||
| $807K-2.4% | $827K+1.1% | $818K+2.6% | $797K+1.0% | $789K+5.6% | ||
| $4.98M-16.3% | $5.95M-17.2% | $7.19M-3.7% | $7.47M+17.4% | $6.36M+4.8% | ||
| —— | —— | —— | $333.83M+3.1% | $323.73M+8.4% | ||
| —— | —— | —— | —— | $435K— | ||
| —— | —— | —— | —— | $1.71M-80.5% | ||
| —— | —— | —— | —— | $1.8M— | ||
| $237.38M+25.7% | $188.91M+14.1% | $165.59M-10.7% | $185.44M+37.8% | $134.62M+8.1% | ||
| $237.38M+25.7% | $188.91M+14.1% | $165.59M-10.7% | $185.44M+37.8% | $134.62M+8.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Krystal Biotech, Inc. generate?
- Krystal Biotech, Inc. (KRYS) generated $250.3M in operating cash flow over the trailing twelve months.
- What is Krystal Biotech, Inc.'s free cash flow?
- After $12.9M of capital expenditures, Krystal Biotech, Inc.'s free cash flow was $237.4M over the trailing twelve months, up 76.3% year over year.
- Where does Krystal Biotech, Inc.'s cash flow data come from?
- Every line is extracted from Krystal Biotech, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
